New 'rules' shape successful management

Article

Manage the patient's environment, manage the patient systemically, manage inflammation first, and communicate effectively with patients may be considered the new "rule"book for ocular surface disease management.

"Remember those four simple rules and you'll be well on your way to successful management of OSD," he said. "If you do those things, in most patients, you'll be pretty close to taking care of the problem. If you don't do those things, you probably won't be as successful no matter what other topical therapeutic options you use," said Dr. Morris, a private practitioner here and managing partner of Morris Education & Consulting Associates and Ocular Technology Associates.

Four-step program

Evaluating patients' systemic well being as well as topical disease is the second important element in OSD management, Dr. Morris said.

"In my experience, OSD is often a manifestation of larger systemic diseases or issues," he continued. "Think like a physician and look for underlying disease that may be manifesting itself on the ocular surface."

Examples of such diseases include systemic allergies, acne rosacea, and various autoimmune disorders.

Treating inflammation first is always crucial to controlling and managing OSD, Dr. Morris said. And finally, effective communication with the patient is crucial.

"As optometrists, we're service providers. If you don't communicate to patients what their condition is, what you're doing about it, what common side effects they should anticipate, and so on, then you're probably not going to do very well managing the disease and the patient. Remember, it's not only about medicine, it's also about customer service," he noted.

Dr. Morris said managing the environment, managing the patient systemically, managing the inflammation first, and communicating effectively with patients may be considered the new "rulebook" for ocular surface disease management. "Remember those four simple rules and you'll be well on your way to successful management."

Get started early

Dr. Morris also is an advocate of early diagnosis and early treatment. He noted that it's usually not the case that dry eye or other OSDs start out as severe. They usually start out mild, but are ignored or mistreated.

"The best way to manage OSD is to manage it early in the course of the disease instead of waiting until a certain severity level is reached," he said.

"Our single biggest problem in managing OSD is that everyone ignores it and waits until it gets so bad that conventional treatments just won't work effectively. Or, optometrists wait to treat and then find they have to load their patients up with five or six different treatment strategies. When diagnosed and treated early, management of OSD is fairly simple and the available treatment regimens are very successful," Dr. Morris said in conclusion.

FYI

Scot Morris, OD, FAAO
Phone: 303/250-0376
E-mail: scot@mecace.com

Dr. Morris has received honorariums as a consultant or advisory board member from Allergan, Aton Pharmaceuticals, Bausch + Lomb Vision Care, CIBA Vision, ECR Vault, Essilor Labs of America, Inspire Pharmaceuticals, Luxottica, and Office Mate Software Solutions. He also receives educational grants for the National Student Practice Management Symposium.

Recent Videos
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
© 2024 MJH Life Sciences

All rights reserved.